Regulatory November date set for FDA decision on Sanofi’s Gaucher drug PharmaphorumThe FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.Rare DiseaseRead full story pharminent May 28, 2026 (Last updated: May 30, 2026) Pharmaphorum The FDA has started a priority review of Sanofi’s brain-acting Gaucher disease therapy venglustat, with an action date of 25th November. Rare Disease Read full story Post navigation Previous: Kailera’s three-pronged obesity shot shows promise in early trialNext: AbbVie snags FDA’s first ADC approval for ultra-rare blood cancer Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026